Phase II study of bevacizumab and irinotecan plus alternate-day S-1 as second-line therapy in patients with metastatic colorectal cancer.

ABSTRACT: Interventions: Alternate-day S-1 (80mg/m2; day 2,4,6...14) combined with irinotecan (150mg/m2; day 1) and bevacizumab (5.0 mg/kg; day 1) Primary outcome(s): Incidence of grade 3 or 4 diarrhea Study Design: Single arm Non-randomized

DISEASE(S): Metastatic Colorectal Cancer

PROVIDER: 2624349 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR